Combination of serum lactate dehydrogenase and sex is predictive of severe disease in patients with COVID-19

Jin Hu, MD, Jun Zhou, MD, Fang Dong, MD, Jie Tan, MD, Shuntao Wang, MD, Zhi Li, MD, Xi Meng Zhang, MD, Huiqiong Zhang, MD, Jie Ming, MD, PhD*, Tao Huang, MD, PhD *

Abstract
Elevated serum lactate dehydrogenase (LDH) was commonly reported in COVID-19 patients. However, the relationship between LDH and the incidence of severe cases has not been characterized in those patients. We retrospectively analyzed the characteristics of patients from a designated isolation medical center for COVID-19 patients diagnosed from February 6 to March 1. Variables accessed within 48 hours on admission were compared between patients with and without the severe disease. Logistic model analyses were performed to examine the prognostic value of LDH for predicting severe disease.

| Parameter                   | Non-severe cases (n=522) | Severe cases (n=50) | OR (95% CI) |
|-----------------------------|--------------------------|--------------------|-------------|
| LDH (IU/l)                  | 217.85 ± 107.11          | 370.20 ± 140.40    | 2.27 (1.10-4.69) |
| Sex                         | Male (31.41 vs 68.59)    | Male (78% vs 22%)  | 2.75 (1.39-5.51) |
| Neutrophils (× 10^9/l)      | 5.21 ± 2.49              | 11.70 ± 5.72       | 2.75 (1.39-5.51) |
| Lymphocytes (× 10^9/l)      | 1.74 ± 0.86              | 0.80 ± 0.37        | 0.38 (0.20-0.72)  |
| Platelets (× 10^9/l)        | 271.01 ± 108.51          | 297.40 ± 103.41    | 1.01 (0.97-1.05)  |

Serum LDH on admission combined with sex is independently associated with severe disease in COVID-19.

Abbreviations: ALB = serum albumin, ALT = alanine aminotransferase, ARDS = acute respiratory distress syndrome, AST = aspartate aminotransferase, BMI = body mass index, BUN = blood urea nitrogen, CHD = chronic heart disease, CK-MB = creatine kinase muscle-brain, COVID-19 = coronavirus disease 2019, CRP = C-reactive protein, HR = hazard ratios, hs-TNI = high-sensitivity troponin I, LDH = lactate dehydrogenase, NPV = negative predictive value, PPV = positive predictive value, ROC = receiver operating characteristic, SARS = severe acute respiratory syndrome, SD = standard derivation, WBC = white blood cell.

Keywords: COVID-19, predict, serum lactate dehydrogenase, severe

1. Introduction
The coronavirus disease 2019 (COVID-19) pandemic continues to take a heavy toll on families, communities, and nations the world over.[1] Globally, as of 2:00 am CEST, Apr 7, 2020, 1,247,242 confirmed cases of COVID-19, including 69,213 deaths, had been reported to WHO.[2] COVID-19 patients were reported that most of them with mild or moderate state, 13.8% with a serious state, 4.7% with a critically ill state by the Chinese Centers for Disease Control, on February 24, 2020.[3] Published research from Wuhan Jingyintan by January 26, 2020, reported that 658 patients were included in their study. Fifty two (7.9%) patients developed critically ill state and 57.7% of critical patients died.[4] Consequently, early detection of seriously and critically ill patients is particularly important for reducing mortality in patients with COVID-19.

New coronavirus pneumonia prevention and control program (7th ed, in Chinese) was published on Mar 4, 2020.[5] The guideline showed the definition of seriously and critically ill patients and the characteristics of clinical indicators that may be used to predict the early stage of infection, as follows:

1. lymphocyte levels that increase progressively;
2. inflammatory factor (interleukin 6, C-reactive protein) levels that increase progressively;
3. serum lactic acid levels that increase progressively;
4. lung lesions that progress rapidly in the short term.

However, recently most published studies had shown that serum lactate dehydrogenase (LDH) increased significantly in serious and critical patients with COVID-19.[6-9] LDH, which is widely expressed in tissues, is a cytoplasmic enzyme. Elevated
LDH was witnessed in some disease processes such as tissue injury, necrosis, hypoxia, malignant tumors. The role of LDH in the involvement of viruses (the human immunodeficiency virus, influenza A virus, and white spot syndrome virus) had been reported. In order to further evaluate those parameters and find a laboratory finding obtained with a convenient and efficient method, we conducted a retrospective study to verify whether serum LDH on admission within 48 hours is a powerful predictor for seriously and critically ill cases in COVID-19.

2. Methods

2.1. Patients

We retrospectively analyzed 252 consecutive patients from the Wuhan Union Hospital, which was converted to a designated hospital for COVID-19 patients. All the patients were confirmed COVID-19 and diagnosed from February 6 to March 1. Patients were excluded when their outcome records, lactate dehydrogenase within 48 hours on admission, or body mass index (BMI) were not available. (Fig. 1) The levels of the LDH were determined by routine laboratory diagnostics (reference range 109 to 245 U/L, Roche Diagnostics, Basel, Switzerland). Severe cases consisted of admission to intensive care unit, or invasive ventilation, or death.

2.2. Demographic and clinical features

The demographic variables were recorded, including age, sex, BMI. Symptoms and signs on admission included fever, dry cough, dyspnea, chest tightness/chest pain, fatigue, headache, and diarrhea. The comorbidities included hypertension, chronic heart disease (CHD), and diabetes. Laboratory data on admission within 48 hours were recorded, including white blood cell (WBC, ×10⁹/L), neutrophils (×10⁹/L), lymphocytes (×10⁹/L), C-reactive protein (CRP, mg/dL), LDH (U/L), hemoglobin (g/L), serum albumin (ALB, g/L), aspartate aminotransferase (AST, U/L), alanine aminotransferase (ALT, U/L), high-sensitivity troponin I (hs-TNI, ng/ml), creatine kinase muscle-brain (CK-MB, U/L), blood urea nitrogen (BUN, mmol/L), and serum creatinine (umol/L). The clinical outcome for the series was the severe disease.

2.3. Statistical analysis

All statistical analyses were performed utilizing SPSS statistical software (version 22.0; IBM Corporation, Armonk, NY, USA). Receiver operating characteristic (ROC) curves were plotted and compared by Stata (version 14). Continuous data were shown as means and standard derivation (SD). Categorical variables were reported as frequency. The differences of characteristics between patients with or without severe disease were compared by Mann–Whitney U test and Student t test. Multiple group comparisons were performed using the Chi-Squared test or Fishers exact test for categorical variables and the Kruskal–Wallis test for continuous data. All variables with statistically significant difference in the univariate analysis model and with clinical value were included for further multivariate logistic regression analysis. Hazard ratios (HR) and 95% confidence intervals (95% CI) were recorded. Then, variables shown to have statistical significance (P < .05) by multivariate analysis entered logistic regression model to obtain prediction probability. ROC was plotted for the range of LDH and prediction probability values. The difference between ROC was analyzed by the Chi-Squared test. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were presented.

Figure 1. Flow diagram illustrating the selection of patients. BMI = body mass index, COVID-19 = coronavirus disease 2019.
2.4. Ethical approval and consent to participate
Informed consent for individual patient was not obtained since all data were retrieved retrospectively from the laboratory test information system without additional blood samples or laboratory analysis. The study was approved by Union hospital Tongji Medical College, Huazhong University of Science and Technology Ethics Committee.

3. Results

3.1. Characteristics by patients with different LDH levels
The baseline characteristics of 182 patients with COVID-19 according to LDH levels (elevated or normal) have been shown in Table 1. The mean age or BMI between groups was no difference. The LDH on admission of males seems to be higher than that of females. Additionally, compared with normal LDH levels, elevated group showed statistically significant difference in severe disease (38.3% vs 9.7%, \( P < .001 \)) and in-hospital mortality (25.8% vs 9.7%, \( P = .007 \)). Comorbidities was not related to elevated LDH levels resulted from COVID-19 patients. In this cohort, most patients presented with fever, dry cough, dyspnea, and fatigue. However, there was no difference in most of the symptoms and signs at the time of admission between the 2 groups.

3.2. Comparison between patients with and without severe disease
Demographic and clinical characteristics according to patients with and without severe disease have been shown in Table 2. The significant differences in age (63.06 ± 14.10 vs 63.62 ± 14.41, \( P = .812 \)) and BMI (23.58 ± 2.78 vs 23.80 ± 3.53, \( P = .649 \)) were not seen. Additionally, there was no difference in the symptoms and signs observed between 2 groups. No difference in comorbidities was witnessed between the non-severe disease group and the severe disease group. Although the duration of hospital stay had no difference (25.06 ± 8.96 vs 22.72 ± 10.36, \( P = .166 \)), the severe disease group tended to have a shorter

Table 1
Basic characteristic of COVID-19 patients according to LDH level (normal range <245 U/L).

| Variables                      | LDH <245 U/L (n = 62) | LDH ≥245 U/L (n = 120) | \( P \) value |
|-------------------------------|------------------------|------------------------|--------------|
| Age, years                    | 61.84 ± 15.74          | 63.93 ± 13.28          | 345          |
| Body mass index               | 23.91 ± 2.82           | 23.51 ± 3.10           | 300          |
| Sex                           |                        |                        | .028         |
| Male                          | 27 (43.5)              | 73 (60.8)              |              |
| Female                        | 35 (56.5)              | 47 (39.2)              |              |
| Smoking                       | 4 (6.5)                | 6 (5.7)                | 956          |
| Symptoms and signs            |                        |                        |              |
| Fever                         | 50 (80.6)              | 101 (84.2)             | 549          |
| Dry cough                     | 46 (77.4)              | 76 (63.3)              | .053         |
| Dyspnea                       | 19 (30.6)              | 74 (61.7)              | <.001        |
| Chest tightness/chest pain    | 21 (33.9)              | 46 (38.7)              | .527         |
| Respiratory rate ≥30 bpm      | 13 (21.0)              | 41 (34.2)              | .65          |
| SpO2                          | 96.82 ± 2.37           | 94.33 ± 6.12           | .002         |
| Fatigue                       | 37 (59.7)              | 67 (55.8)              | .619         |
| Headache                      | 7 (11.3)               | 7 (5.8)                | 241          |
| Diarrhea                      | 11 (17.7)              | 16 (13.3)              | .428         |
| Heart rate, beats per min     | 91.74 ± 16.79          | 91.08 ± 17.34          | .806         |
| Mean arterial pressure, mm Hg | 95.03 ± 12.53          | 96.80 ± 13.50          | .07          |
| Comorbidities                 |                        |                        |              |
| Hypertension                  | 22 (35.5)              | 57 (47.5)              | .081         |
| Chronic heart disease         | 6 (9.7)                | 22 (18.3)              | .091         |
| Diabetes                      | 8 (12.9)               | 23 (19.2)              | .197         |
| Laboratory data               |                        |                        |              |
| White blood cell, \( \times 10^9/L \) | 6.83 ± 3.67          | 10.28 ± 14.02          | .059         |
| Neutrophil count, \( \times 10^9/L \) | 4.85 ± 3.58          | 7.32 ± 4.93           | <.001        |
| Lymphocyte count, \( \times 10^9/L \) | 1.73 ± 4.08          | 2.29 ± 11.49          | .711         |
| Hemoglobin, g/L               | 117.23 ± 21.17         | 114.00 ± 23.58         | .366         |
| Total protein, g/L            | 62.75 ± 6.23           | 62.45 ± 7.98           | .796         |
| Serum albumin, g/L            | 32.35 ± 6.68           | 29.10 ± 5.91           | .001         |
| Aspartate aminotransferase, U/L | 29.69 ± 17.16         | 184.70 ± 1442.66       | .399         |
| Alanine aminotransferase, U/L | 41.76 ± 32.46         | 135.90 ± 636.38        | .378         |
| C-reactive protein, mg/dL     | 26.49 ± 39.40          | 64.91 ± 49.68          | .001         |
| High-sensitivity troponin I, ng/ml | 58.83 ± 211.60      | 335.50 ± 1240.23       | .131         |
| Creatine kinase muscle-brain, U/L | 10.88 ± 9.77         | 25.93 ± 64.27          | .069         |
| Blood urea nitrogen, mmol/L   | 6.56 ± 8.26            | 9.08 ± 8.83            | .063         |
| Serum creatinine, umol/L      | 75.05 ± 55.36          | 103.31 ± 183.03        | .237         |
| Outcomes                      |                        |                        |              |
| Severe cases                  | 6 (9.7)                | 46 (38.3)              | <.001        |
| In-hospital mortality         | 6 (9.7)                | 31 (25.8)              | .007         |

COVID-19 = 2019 novel coronavirus disease, LDH = lactate dehydrogenase.
Table 2
Clinical data of the patients with and without severe disease.

| Variables                  | Non-severe disease (n = 130) | Severe disease (n = 52) | P value |
|----------------------------|------------------------------|-------------------------|---------|
| Age, years                 | 63.06 ± 14.10                | 63.62 ± 14.41           | .812    |
| Body mass index            | 23.58 ± 3.78                 | 23.80 ± 3.53            | .649    |
| Duration in hospital       | 25.08 ± 9.96                 | 22.72 ± 10.36           | .166    |
| Sex                       |                              |                         | <.001   |
| Male                      | 58 (44.6)                    | 42 (80.8)               |         |
| Female                    | 72 (55.4)                    | 10 (19.2)               |         |
| Smoking                   | 8 (6.2)                      | 4 (7.7)                 | .706    |
| Symptoms and signs         |                              |                         |         |
| Fever                     | 106 (81.5)                   | 45 (88.5)               | .418    |
| Dry cough                 | 93 (71.5)                    | 31 (59.6)               | .119    |
| Dyspnea                   | 62 (47.7)                    | 31 (59.6)               | .146    |
| Chest tightness/chest pain| 49 (38.0)                    | 18 (34.6)               | .671    |
| Respiratory rate ≥30 bpm   | 39 (30.0)                    | 15 (28.8)               | .878    |
| SpO2                      | 96.30 ± 2.75                 | 92.37 ± 8.29            | <.001   |
| Fatigue                   | 75 (57.7)                    | 29 (55.8)               | .813    |
| Headache                  | 11 (8.5)                     | 3 (5.8)                 | .538    |
| Diahrea                   | 21 (16.2)                    | 6 (11.5)                | .429    |
| Heart rate, beats per min | 91.14 ± 16.64                | 91.73 ±18.40            | .834    |
| Mean arterial pressure, mm Hg | 97.90 ± 13.23              | 96.51 ± 13.41           | .527    |
| Comorbidities              |                              |                         |         |
| Hypertension               | 56 (43.1)                    | 23 (44.2)               | .508    |
| Chronic heart disease      | 16 (12.3)                    | 12 (23.1)               | .059    |
| Diabetes                   | 23 (17.7)                    | 8 (15.4)                | .446    |
| Laboratory data            |                              |                         |         |
| White blood cell, ×10^9/L  | 8.62 ± 13.23                 | 10.33 ± 6.28            | .374    |
| Neutrophil count, ×10^9/L  | 5.42 ± 3.26                  | 9.19 ± 6.33             | <.001   |
| Lymphocyte count, ×10^9/L  | 2.66 ± 11.38                 | 0.73 ± 0.51             | .233    |
| Hemoglobin, g/L            | 116.28 ± 22.25               | 112.15 ± 24.04          | .271    |
| Total protein, g/L         | 63.22 ± 6.93                 | 60.88 ± 8.32            | .054    |
| Serum albumin, g/L         | 31.41 ± 0.20                 | 27.18 ± 5.74            | <.001   |
| Aspartate aminotransferase, U/L | 34.63 ± 18.76              | 375.06 ± 2188.74        | .077    |
| Alanine aminotransferase, U/L | 44.42 ± 33.31              | 252.04 ± 1267.43        | .063    |
| Lactate dehydrogenase, U/L | 321.85 ± 186.24             | 647.35 ±424.26          | <.001   |
| C-reactive protein, mg/dL  | 38.63 ± 43.14                | 83.20 ± 51.01           | <.001   |
| High-sensitivity troponin I, ng/ml | 151.56 ± 1043.28         | 483.09 ± 1008.34        | .076    |
| Creatine kinase muscle-brain, U/L | 12.47 ± 16.72          | 41.65 ± 92.77           | .001    |
| Blood urea nitrogen, mmol/L | 6.94 ± 8.37                 | 11.41 ± 8.76            | .002    |
| Serum creatinine, umol/L   | 86.19 ± 156.10               | 112.41 ± 142.61         | .296    |

duration. In laboratory data, the statistically significant differences were observed in neutrophil count (5.42 ± 3.26 vs 9.19 ± 6.33, P < .001), ALB (31.41 ± 6.20 vs 27.18 ± 5.74, P < .001), LDH (321.85 ± 186.24 vs 647.35 ± 424.26, P < .001), CRP (38.63 ± 43.14 vs 83.20 ± 51.01, P < .001), CK-MB (12.47 ± 16.72 vs 41.65 ± 92.77, P = .001), and BUN (6.94 ± 8.37 vs 11.41 ± 8.76, P = .002) between non-severe disease group and severe disease group. Although the severe disease group had a lower value of lymphocyte count, there was no difference (2.66 ± 11.38 vs 0.73 ± 0.51, P = .233) (Supplement 1, http://links.lww.com/MD/F37 and Supplement 2, http://links.lww.com/MD/F38).

3.3. Admission serum LDH combined with sex as an independent prognostic factor

Univariate analysis showed that sex (Female as reference, HR 5.214; 95% CI 2.410, 11.277; P < .001), neutrophil count (HR 1.258; 95% CI 1.140, 1.388; P < .001), lymphocyte count (HR 0.241; 95% CI 0.113, 0.515; P < .001), LDH (HR 1.005; 95% CI 1.003, 1.007; P < .001), CRP (HR 1.018; 95% CI 1.011, 1.026; P < .001), and ALB (HR 1.012; 95% CI 1.005, 1.020; P = .001) were correlated with the incidence of severe disease. In order to further explore the relationship between serum LDH and the incidence of severe disease, we utilized the multivariate logistic regression model after univariate analysis. In multivariate analysis, only sex (Female as reference, HR 5.389; 95% CI 1.949, 14.905; P = .001) and LDH (HR 1.005; 95% CI 1.003, 1.007; P < .001) were as independent prognostic factors for severe disease. (Table 3)

3.4. ROC of serum LDH and a combination of serum LDH and sex in predicting severe disease

ROC was plotted for the range of LDH and prediction probability of a combination of serum LDH and sex values. The serum LDH predicted severe cases with an area under the curve (AUC) of 0.7999. The sensitivity, specificity, PPV, and NPV were 67.3%, 87.7%, 68.6% and 87.0%, respectively. A combination of serum LDH and sex predicted severe cases with an AUC of 0.849 (P = .0238). The sensitivity, specificity, PPV, and NPV were 94.2%, 60.0%, 48.5%, and 96.3%, respectively. (Fig. 2)
4. Discussion

In this study, we proved that serum LDH and male sex were independent prognostic factors for patients with COVID-19. A combination of serum LDH accessed on admission and sex had a better predictive performance than the serum LDH for worse outcome of COVID-19. Additionally, elevated neutrophil count and CRP levels, and reduced lymphocyte count were not associated with severe disease in COVID-19. We also demonstrated that age or BMI was not a risk factor for seriously and critically ill patients with COVID-19.

The utility of the serum LDH in virus was first investigated by Zaman et al.[13] in 1988. They noticed that the level of serum LDH was useful as a marker of P. jirovecii pneumonia in patients infected with the human immunodeficiency virus. Ede et al.[17] reported that the severity of nasopharyngeal cellular injury during viral upper respiratory tract infection, as measured by LDH levels in nasopharyngeal secretions, was related to acute otitis media complication. They implied that there was a positive correlation between levels of LDH and all cytokines (interleukin (IL)-1, IL-6, and tumor necrosis factor-α). LDH levels in nasopharyngeal secretions were positively associated with acute otitis media risk. Andrejčáková et al.[18] suggested that LDH levels in the blood serum and tissue extracts could predict the immune status of jejunal mucosa during enterotoxigenic Escherichia coli and coronavirus infection in piglets.

The elevated serum LDH was observed in some studies about severe acute respiratory syndrome (SARS). A previous study of SARS data from 2003 found that lymphopenia, elevated LDH, AST, and creatinine kinase levels were common in serious cases.[19] Liu et al.[20] suggested that 58% of patients diagnosed with SARS presented elevated LDH on admission. However, another study from Hong Kong that included 156 SARS-positive and 62 SARS-negative patients showed that the positive patients had a lower lymphocyte count and a lower LDH level.[21] Those results illustrated that the serum LDH may be applied to patients infected with the novel coronavirus.

The laboratory findings, including elevated WBC, neutrophils, CRP, LDH, and total protein, and reduced lymphocyte levels were common in the severe cases of COVID-19. These results were confirmed by the previous reports.[22,23] The prevention and control program[5] also suggested that lymphocytes, CRP, and lactic acid levels were correlated with serious and critical illness in COVID-19. In addition, a study from Wu et al.[7] which included 201 patients with confirmed COVID-19 pneumonia, showed that the serum LDH was one of the risk factors correlated with the development of acute respiratory distress syndrome (ARDS) and progression from ARDS to death. Yuan et al.[24] conducted a retrospective study which aimed to evaluate the relationship between viral clearance and blood biochemical index in patients with COVID-19. They implied that the COVID-19 mRNA clearance ratio was significantly associated with the decline of serum LDH levels. However, in our study, elevated neutrophil count and CRP levels, and reduced lymphocyte count were not associated with severe disease in COVID-19 after the multivariate logistic regression analysis.

Published studies reported that the average age of severe cases was significantly older than in non-severe cases.[7,25] Another study showed that age below 40 or above 60 years old was not related to severe cases.[22] In our study, age did not present as an independent risk factor after multivariable analysis. Zhou et al.[26] implied that older age was one of the characteristics that could identify at an early stage those patients who have a poor prognosis. The possible reason was that the difference did not observe in patients with underlying comorbidities. The role of sex in patients with COVID-19 remains controversial. Some studies reported that compared with general status cases, the male gender was common in severe cases.[7,27] On the other hand, other studies suggested that there was no significant difference in gender.[22,28,29] In our study, comparing to non-severe cases, the male gender was common in severe cases. In addition, sex was an independent risk factor for severe disease after multivariable analysis. BMI has long been considered to be one of the strongest risk factors for serious and critical illness. As researches[30–32] shown, for intensive care unit patients receiving endotracheal intubation, higher BMI was correlated with higher mortality and longer length of stay. Liu et al.[33] reported that severe patients

Table 3

| Variables                        | Univariate analysis Hazard ratio (95%CI) | P value | Multivariate analysis Hazard ratio (95%CI) | P value |
|----------------------------------|----------------------------------------|---------|------------------------------------------|---------|
| Age, years                       | 1.003 (0.980, 1.026)                   | .811    |                                          |         |
| Body mass index                  | 1.025 (0.921, 1.142)                   | .647    |                                          |         |
| Sex (Female as reference)        | 5.214 (2.410, 11.277)                  | <.001   | 5.389 (1.949, 14.905)                    | .001    |
| Neutrophil count, × 10^9/L       | 1.258 (1.140, 1.388)                   | <.001   | 1.103 (0.966, 1.260)                     | .146    |
| Lymphocyte count, × 10^9/L       | 0.241 (0.113, 0.515)                   | <.001   | 0.812 (0.345, 1.909)                     | .633    |
| Lactate dehydrogenase, U/L       | 1.005 (1.003, 1.007)                   | <.001   | 1.008 (0.998, 1.018)                     | .117    |
| C-reactive protein, mg/dl        | 1.018 (1.011, 1.026)                   | <.001   | 0.922 (0.850, 1.000)                     | .050    |
| Serum albumin, g/L              | 1.012 (1.005, 1.020)                   | .001    |                                          |         |
| Total protein, g/L              | 0.957 (0.915, 1.001)                   | .056    |                                          |         |
with COVID-19 had higher BMI. The above results led to consider excluding patients without available values of BMI. However, disease severity was not related to BMI in the univariate analysis model.

5. Strengths

Our study also has several strengths. Firstly, as far as we know, this is the first detailed study of the impact of serum LDH on severe disease in COVID-19 patients. Secondly, all laboratory findings were collected on admission within 48 hours. Thirdly, we found that the predictive performance of a combination of serum LDH and sex was higher than that of serum LDH.

6. Limitation

Our study has certain limitations. First, this study design was that of a retrospective study, such that more detailed therapeutic responses will be needed. Several patients developed disorders of consciousness upon admission, which may have resulted in the involuntary omission of patients information (in particular, a detailed medical history). Missing data can lead to a bias in results. Second, the lack of effective antiviral[34] and corticosteroid[26] use may have also contributed to the poor clinical outcomes observed in certain patients. Moreover, the case fatality rate reported in our study is not representative of the true mortality of COVID-19 patients, due to the large number of critically ill patients found in the Wuhan Union Hospital. Lastly, the interpretation of our findings may also be limited by the sample size. Our research provides a preliminary insight into the identification of variables for the prediction of COVID-19 patient outcomes and serves as a basis for further detailed clinical and pathophysiological studies, which will also be necessary.

7. Conclusions

In conclusion, our present study suggests that a combination of serum LDH on admission and sex is independently correlated with severe status in patients with COVID-19. The combination may serve as a valuable tool for a rapid assessment of severe status in patients.

Acknowledgments

We thank the patients, the nurses and physicians who provided care for the patients, and the investigators at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Author contributions

Conceptualization: Tao Huang.
Data curation: Jun Zhou, Fang Dong, Jie Tan, Shuntao Wang, Huiqiong Zhang.
Formal analysis: Jin Hu, Jun Zhou.
Methodology: Jun Zhou, Shuntao Wang, Zhi Li, Ximeng Zhang, Tao Huang.
Visualization: Jie Ming, Tao Huang.
Writing – original draft: Jin Hu.
Writing – review & editing: Jie Ming, Tao Huang.

References

[1] WHO. Director-General’s opening remarks at the media briefing on COVID-19 6 April 2020. Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—6-april-2020. Accessed April 6, 2020.
[2] WHO, Health Emergency Dashboard (WHO (COVID-19) Homepage) 2020. Available at: https://who.sprinklr.com/. Accessed April 7, 2020.
[3] Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese center for disease control and prevention. JAMA 2020;323:1239-42.
[4] Yang Y, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475-81.
[5] New coronavirus pneumonia prevention and control program (7th ed) (in Chinese), 2020; http://www.nhc.gov.cn/zyyjgs/yzyjgszixun/202003/a31191442c29474b98fbed53579d5495.shtml. Accessed April 11, 2020.
[6] Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol 2020;138:575-8.
[7] Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020;180:594-43.
[8] Wang Z, Yang B, Li Q, et al. Clinical features of 69 cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis 2020;71:769-77.
[9] Wang D, Hu H, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020;323:1061-9.
[10] Karlsson M, Wiberg-Izel E, Chakkarapani E, et al. Lactate dehydrogenase predicts hypoxic ischaemic encephalopathy in newborn infants: a preliminary study. Acta Paediatr 2010;99:1139-44.
[11] Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006;107:2279-85.
[12] Eigentler TK, Figl A, Krex D, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 2011;117:1697-703.
[13] Zaman MK, White DA. Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia. Diagnostic and prognostic significance. Am Rev Respir Dis 1988;137:796-800.
[14] Watanabe W, Sudo K, Asawa S, et al. Use of lactate dehydrogenase to evaluate the anti-viral activity against influenza A virus. J Virol Methods 1995;51:185-91.
[15] Hernández-Palomares MLE, Godoy-Jiménez S, et al. Regulation of lactate dehydrogenase in response to WSSV infection in the shrimp Litopenaeus vannamei. Fish Shellfish Immunol 2018;74:401-9.
[16] Guan WJ, Liang WH, Zhao Y, et al. Comorbidities and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J 2020;55:200057.
[17] Ede LC, O’Brien J, Chommaître T, et al. Lactate dehydrogenase as a marker of nasopharyngeal inflammatory injury during viral upper respiratory infection: implications for acute otitis media. Pediatr Res 2013;73:349–54.
[18] Andrejčáková Z, Sopková D, Vlčková R, et al. Symbiotics suppress the release of lactate dehydrogenase, promote non-specific immunity and integrity of jejunal mucosa in piglets. Anim Sci J 2016;87:1137-66.
[19] Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. Radiology 2003;248:1995–2005.
[20] Liu CL, Lu YT, Peng MJ, et al. Clinical and laboratory features of severe acute respiratory syndrome virus-a vis-a-vis onset of fever. Chest 2004;126:509–17.
[21] Tsang OT, Chau TN, Choi KW, et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis 2003;9:1381-7.
[22] Zhang G, Zhang J, Wang B, et al. Analysis of clinical characteristics and laboratory findings of 93 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respir Res 2020;21:74.
[23] Xiong Y, Sun D, Liu Y, et al. Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes. Invest Radiol 2020;55:332-9.
Yuan J, Zou R, Zeng L, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm Res 2020;69:599–606.

Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest 2020;130:2620–9.

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.

Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091.

Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 2020;92:797–806.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.

Na SJ, Park TK, Lee JM, et al. Association between body mass index and mortality in patients requiring cardiac critical care. PLoS One 2019;83:743–8.

Mulki R, Baumann AJ, Alnabelsi T, et al. Body mass index greater than 35 is associated with severe Clostridium difficile infection. Aliment Pharmacol Ther 2017;45:73–81.

Irving SY, Daly B, Verger J, et al. The association of nutrition status expressed as body mass index z score with outcomes in children with severe sepsis: a secondary analysis from the Sepsis Prevalence, Outcomes, and Therapies (SPROUT) study. Crit Care Med 2018;46:e1029–39.

Liu M, He P, Liu HG, et al. [Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia]. Zhonghua Jie He Hu Xi Za Zhi 2020;43:209–14.

Kalil AC. Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA 2020;323:1897–8.